Blog

What’s Your Hunger Type?

What’s Your Hunger Type?

Have you ever sat with a friend during a mid-afternoon break and watched her eat just one cookie, while you’re trying to stop yourself from devouring the bagful? Or been at a buffet with someone who has only one serving of her main course and doesn’t go back for more? Maybe you know someone who never gains weight, even though she eats as much as you (so unfair!). Or you have that friend who loses weight when she’s upset, because she ‘stress starves’ rather than stress eats. It turns out the reason these people have different eating behaviors to you is because they demonstrate different types of hunger and/or metabolism from yours.

Obesity Phenotypes 

Dr Andres Acosta, MD, PhD, is the director of the Precision Medicine for Obesity Laboratory at the Mayo Clinic in Rochester, MN. He and his team have identified various observable characteristics (i.e., phenotypes) that contribute to the way people feel hungry (take in calories) or use energy (burn off calories).1 Using a combination of eating studies, imaging and various questionnaires in a group of 450 people with a BMI >30 kg/m2, they were able to distinguish four different ‘obesity phenotypes’ that contribute to being overweight. Three of them relate to energy intake and one to energy expenditure.

Hungry Brain – Abnormal Satiation

Hungry Brain phenotypes don’t feel full in a normal way. Their ‘satiation’ (the number of calories it takes to feel full, by Dr. Acosta’s definition) is off. So, when they sit down to eat, they don’t stop till well after everyone else has had enough. They’re the ones going back for more and more servings at a buffet. In fact, in Dr. Acosta’s study, this group consumed 62% more calories before reaching fullness. 

Hungry Gut – Abnormal Satiety 

Dr. Acosta defines satiety as how long you feel full for (as opposed to satiation, how much food it takes to make you feel full). If you have a meal and stop eating because you feel full, but an hour or two later you want to eat a whole lot more, then you have the Hungry Gut phenotype, that is, abnormal satiety. You’re the one who joins your friend for a coffee two hours after lunch but want to eat the bag of cookies with it while watching her eat just one of them. Your stomach is the culprit: it’s emptying too quickly, which means one of the main messages to stop (slowing stomach emptying) is lacking. The people with the Hungry Gut phenotype emptied their stomachs 31% faster in Dr. Acosta’s study. 

Emotional Hunger – Hedonic Eating 

It’s not uncommon to be an ‘emotional eater’—someone who turns to food to get through the stresses of life or to reward themselves—judging by the number of online articles about conquering emotional eating. Dr. Acosta’s group used questionnaires related to anxiety and depression, eating and behavior to gauge if someone had the Emotional Hunger phenotype. This group had almost 3 times higher levels of anxiety as well as increased symptoms of depression and lower levels of self-esteem and body image. 

Slow Burn - Energy Expenditure 

The fourth phenotype is related to energy expenditure. These are people who seem to gain weight even if they eat the same number of calories as their slimmer friends. Obese participants with this phenotype demonstrated 12% lower resting energy expenditure, were less frequently active, less likely to do structured exercise and if they did, performed it for less time. Not surprisingly, this group had lower muscle mass. 

Overall, 85% of the 450 participants fit into at least one of these 4 phenotypes. The most common one was Hungry Gut, but 27% of people slotted into more than one phenotype (Figure 1). In fact, 9% met the criteria for all 4 phenotypes!  

Figure 1: Distribution of obesity phenotypes in 450 patients with obesity.1   

Weight Loss Prescribing Based on Obesity Phenotype 


Dr. Acosta’s team also looked at using phenotypes to guide the choice of weight loss medication. At 12 months, 79% of 84 participants with phenotype-guided treatment had lost >10% of their weight, versus 35% of the 228 who had standard treatment. Overall, phenotype-guided medication increased total weight loss by 75%.  

There’s been a lot of attention focused on the appetite-regulating gut hormone glycogen-like peptide-1 (GLP-1) lately. Normally, GLP-1 increases when we eat, activating a feeling of fullness in parts of the brain that control eating and slowing down stomach emptying, both of which cause us to stop eating more. Medications such as semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) mimic GLP-1, and the all-natural plant-derived supplement Calocurb increases natural GLP-1 production. It makes sense then, that these compounds would be effective in the Hungry Gut and Hungry Brain phenotypes, because they slow down stomach emptying, and decrease ‘food noise’.  

However, not everyone loses weight by taking GLP-1 agents. In one study, even on the highest dose of tirzepatide, close to 17% of patients didn’t achieve 10% or more weight loss and almost 10% didn’t even achieve 5% weight loss.2 Could these non-responders be one of the other obesity phenotypes? A 2022 study found that people with higher emotional eating scores were less sensitive to the brain effects of liraglutide (an older GLP-1mimic).3 What’s more, GLP-1 mimics do not seem to directly increase energy expenditure. Perhaps the non-responders to GLP-1 agents fall into the Emotional Hunger and/or Slow Burner groups.   

Conclusion 


If you’re on a weigh loss journey, it makes sense to try to figure out which obesity phenotype you seem to be, even if it’s more of a guestimate than the scientific approach that Dr. Acosta uses. If you’re the Hungry Gut or Hungry Brain phenotype, GLP-1 agents should be helpful. If you experience Emotional Hunger or seem to be a Slow Burner, you’ll likely benefit from additional support, such as behavioral therapy and a monitored exercise program, or alternative medications.  

 
References: 

1. Acosta A, Camilleri M, Abu Dayyeh B, et al. Selection of antiobesity medications based on phenotypes enhances weight loss: A pragmatic trial in an obesity clinic [published correction appears in Obesity (Silver Spring). 2021 Sep;29(9):1565-1566. doi: 10.1002/oby.23236] [published correction appears in Obesity (Silver Spring). 2022 Jul;30(7):1521. doi: 10.1002/oby.23498]. Obesity (Silver Spring). 2021;29(4):662-671. doi:10.1002/oby.23120 
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 
3. van Ruiten CC, Ten Kulve JS, van Bloemendaal L, Nieuwdorp M, Veltman DJ, IJzerman RG. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial. Psychoneuroendocrinology. 2022;137:105667.doi:10.1016/j.psyneuen.2022.105667